Loading...
•
Dec 31, 2019
Tandem Diabetes Q4 2019 Earnings Report
Tandem Diabetes' financial results for Q4 2019 and full year 2019 were announced.
Key Takeaways
Tandem Diabetes Care reported a 42% increase in sales for the fourth quarter of 2019, reaching $108.4 million, and a net income of $2.7 million. The company's worldwide pump shipments increased by 21% compared to the same period in 2018. They are guiding for sales between $450 million and $465 million for the year ending December 31, 2020.
Worldwide pump shipments increased 21% to 19,602 pumps.
Sales increased 42% to $108.4 million.
Gross margin improved 1 point to 56% of sales.
Adjusted EBITDA improved to 21% of sales.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
For the year ending December 31, 2020, the Company is providing its financial guidance as follows:
Positive Outlook
- Sales are estimated to be in the range of $450 million to $465 million, which represents an annual sales growth of 24 percent to 28 percent compared to 2019
- Includes international sales of approximately $70 million to $75 million
- Gross margin is estimated to be approximately 54 percent
- Adjusted EBITDA is estimated to be 12 percent to 14 percent
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $60 million
Challenges Ahead
- Approximately $50 million in non-cash, stock-based compensation expense
- Approximately $10 million of depreciation and amortization
Revenue & Expenses
Visualization of income flow from segment revenue to net income